Association Gercor — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

0 Completed trials

1 Countries active

16 Unique IMPs

N/A Results reported

Phase II

Phase II: 7

Top IMPs

CARBOPLATIN 2 CISPLATIN 2 ETOPOSIDE 2 FLUOROURACIL 2 LEVOLEUCOVORIN 2 CIPROFLOXACIN 1 GEMCITABINE 1 IPILIMUMAB 1 IRINOTECAN 1 IRINOTECAN HYDROCHLORIDE TRIHYDRATE 1 MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200 1 NIVOLUMAB 1

All trials

7 total

Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc… Not authorised

2024-515603-19-00 Phase II 1 country CARBOPLATIN; CISPLATIN; ETOPOSIDE
Evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendoc… Pending

2024-515603-19-01 Phase II 1 country CARBOPLATIN; CISPLATIN; ETOPOSIDE
Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. (NIPISAFE) Pending

2024-518138-10-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB
Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct… Pending

2024-518139-12-00 Phase II 1 country FLUOROURACIL; IRINOTECAN HYDROCHLORIDE TRIHYDRATE; LEVOLEUCOVORIN; MPS-112, MPS-…
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting

2024-520128-27-00 Phase II 1 country
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting

2024-517766-41-00 Phase II 1 country CIPROFLOXACIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LEVOLEUCOVORIN; OXALIPLATI…
Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer resistant to anti-PD1 monotherapy: An open-label phas… Recruiting

2024-516313-20-00 Phase II 1 country

Showing 1–7 of 7 trials

← All sponsors A–Z